Marta Araujo Castro

HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL
Country flagSpain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (24)

Year:

2026

Medical treatment of hypercortisolism may be necessary for a high proportion of patients with Cushing syndrome (CS), including those who are not candidates for curative surgery. It may also be used in the presurgical period when hypercortisolism is severe, as long-term treatment following surgical failure or recurrence after surgery, or while waiting for the effects of pituitary radiation in Cushing disease. Currently available medical treatments include adrenal steroidogenesis inhibitors that block cortisol secretion (ketoconazole, levoketoconazole, metyrapone, osilodrostat, mitotane, and etomidate), drugs that modulate pituitary ACTH secretion (pasireotide and cabergoline), and drugs that block peripheral glucocorticoid receptors (mifepristone). In addition, there are other medical treatments in development that target pituitary signaling pathways, ACTH or its adrenal receptor, or the conversion of cortisol from cortisone by 11ßHSD1. Steroidogenesis inhibitors can be administered using either a titration or a block-and-replace approach. Titration requires adjusting the daily drug dose with the aim of normalizing circulating cortisol levels, whereas the block-and-replace strategy uses higher drug doses to fully suppress endogenous cortisol production, followed by glucocorticoid supplementation. In this review, we summarize the main indications for medical treatment in CS, the mechanism of drug action, efficacy, recommended doses, and safety of the currently available drugs, as well as potential future treatments. We also discuss titration and block-and-replace approaches for control of hypercortisolism and provide recommendations for the use and monitoring of medical treatment in CS, including patients with endogenous hypercortisolism in special situations such as pregnancy, cyclic CS, and mild autonomous cortisol secretion.

Year:

2026

Year:

2026

Year:

2026

Pituitary apoplexy (PA) is a rare but potentially life-threatening endocrine emergency caused by sudden hemorrhage or infarction usually within a pituitary tumor. Clinical presentation is highly variable, ranging from isolated headache to severe visual loss or altered consciousness. Prompt recognition, multidisciplinary evaluation, and timely management are essential to improve outcomes. Recent prospective and real-world studies have challenged the traditional view that urgent surgery is always required. Conservative management has been proposed to be a safe and effective option, although comparisons with the outcomes after surgical intervention are limited by differences in the severity of the clinical picture at presentation of the PA. Clinical decisions remain complex and must consider tumor size, symptom progression, radiological features, and individual comorbidities. The Pituitary Apoplexy Score (PAS) helps guide management but has limitations, as it does not capture key variables such as persistent headache or evolving visual symptoms. Immediate management focuses on hemodynamic stabilization, stress-dose glucocorticoid administration, and neuro-ophthalmological monitoring. Surgical decompression should be considered in patients with progressive visual deterioration or altered consciousness. Follow-up must include hormonal reassessment, ophthalmological evaluation, and imaging surveillance. Although rare, recurrence of PA and tumor regrowth may occur, requiring long-term monitoring. This review provides an updated and pragmatic approach for the diagnosis, acute care, and long-term follow-up of PA, summarizing current evidence and highlighting ongoing controversies, including surgical timing and predictors of conservative treatment failure.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (20)

Betina Biagetti

-

SPAIN
View details

Jung Hee Kim

Seoul National University Hospital

SOUTH KOREA
View details

John Newell-Price

Professor of Endocrinology

University of Sheffield

UNITED KINGDOM
View details

Cristina Lamas Oliveira

F.E.A

University of Castilla-La Mancha

SPAIN
View details

NIKI KARAVITAKI

University of Birmingham

UNITED KINGDOM
View details

Mónica Marazuela

Universidad Autónoma de Madrid

SPAIN
View details

Mirko Parasiliti-Caprino

MD PhD

University of Turin

ITALY
View details

Maria de la Iglesia Vaya

Head of Lab

Fisabio

SPAIN
View details

Fabio Bioletto

University of Turin

ITALY
View details

Holger Schneider

LMU University Hospital

GERMANY
View details

Silvia Monticone

Research Scientist

University of Turin

ITALY
View details

Georgios Tsermoulas

University of Birmingham

UNITED KINGDOM
View details

Manel Puig-Domingo

Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol

SPAIN
View details

Víctor Rodríguez-Laval

AUT University

SPAIN
View details

Adina F Turcu

University of Michigan

UNITED STATES
View details

Silvana Sarria Estrada

Hospital Universitari Vall d'Hebron

SPAIN
View details

Piotr Kmieć

assistant professor

Medical University of Gdansk

POLAND
View details

Gemma C. Monte-Rubio

Head of Bioimaging

Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol

SPAIN
View details

Rebeca Martínez-Hernández

Universidad Autónoma de Madrid

SPAIN
View details

Julie Refardt

Researcher

University Hospital Basel

SWITZERLAND
View details